Jay S. Skyler
University of Miami
H-index: 82
North America-United States
Top articles of Jay S. Skyler
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Evidence for C-peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes | Diabetes | Esther Latres Carla J Greenbaum Maria L Oyaski Colin M Dayan Helen M Colhoun | 2024/2/13 |
Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes | Vikas S Sridhar Christine P Limonte Per-Henrik Groop Hiddo JL Heerspink Richard E Pratley | 2024/1 | |
HLA Class II (DR, DQ, DP) Genes Were Separately Associated With the Progression From Seroconversion to Onset of Type 1 Diabetes Among Participants in Two … | Diabetes Care | Lue Ping Zhao George K Papadopoulos Jay S Skyler Alberto Pugliese Hemang M Parikh | 2024/5/1 |
Methods for delaying onset of type 1 diabetes | 2023/1/19 | ||
825-P: Novel Autologous Dendritic Cell Therapy AVT001 for Type 1 Diabetes | Diabetes | JASON L GAGLIA MIKAYLA MACKEY HEATHER L DALEY NORA BRYANT DAVID Y KIM | 2023/6/20 |
Treatment and prevention of type 1 diabetes in the 21st century | David A Baidal Jay M Sosenko Jay S Skyler | 2023/1/1 | |
20-OR: Loss of Characteristic ß-Cell Function in Autoantibody-Positive (Ab+) Individuals during the Progression to Type 1 Diabetes (T1D) | Diabetes | HEBA M ISMAIL DAVID D CUTHBERTSON JAY S SKYLER CARMELLA EVANS-MOLINA JAY SOSENKO | 2023/6/20 |
Phenotypes associated with zones defined by area under the curve glucose and C-peptide in a population with islet autoantibodies | Diabetes care | Jay M Sosenko David Cuthbertson Emily K Sims Heba M Ismail Brandon M Nathan | 2023/5/1 |
C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis | The Lancet Diabetes & Endocrinology | Peter N Taylor Kimberly S Collins Anna Lam Stephen R Karpen Brianna Greeno | 2023/12/1 |
Abatacept for delay of type 1 diabetes progression in stage 1 relatives at risk: a randomized, double-masked, controlled trial | Diabetes care | William E Russell Brian N Bundy Mark S Anderson Laura A Cooney Stephen E Gitelman | 2023/5/1 |
Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial | Diabetes research and clinical practice | Hiddo JL Heerspink Andreas L Birkenfeld David ZI Cherney Helen M Colhoun Linong Ji | 2023/10/1 |
The effect of age on longitudinal measures of beta cell function and insulin sensitivity during the progression of early stage type 1 diabetes | Diabetologia | Ele Ferrannini Andrea Mari Gabriela SF Monaco Jay S Skyler Carmella Evans-Molina | 2023/3 |
Importance of residual insulin secretion in type 1 diabetes | The Lancet Diabetes & Endocrinology | Jay S Skyler | 2023/7/1 |
Correction to: The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes … | Diabetologia | Richard IG Holt J Hans DeVries Amy Hess-Fischl Irl B Hirsch M Sue Kirkman | 2022 |
Association of HLA-DQ Heterodimer Residues− 18β and β57 With Progression From Islet Autoimmunity to Diabetes in the Diabetes Prevention Trial–Type 1 | Diabetes care | Lue Ping Zhao Jay Skyler George K Papadopoulos Alberto Pugliese James Antonio Najera | 2022/7/7 |
Evolving Approaches to Type 1 Diabetes Management | Jay S Skyler | 2022/5/20 | |
We assessed whether Index60, a composite measure of fasting C-peptide, 60-min C-peptide, and 60-min glucose, could improve the metabolic staging of type 1 diabetes for … | Diabetes Care | Brandon M Nathan Maria J Redondo Heba Ismail Laura Jacobsen Emily K Sims | 2022/2 |
Persistence of β-cell responsiveness for over two years in autoantibody-positive children with marked metabolic impairment at screening | Diabetes care | Emily K Sims David Cuthbertson Jamie L Felton Heba M Ismail Brandon M Nathan | 2022/12/1 |
Index60 identifies individuals at appreciable risk for stage 3 among an autoantibody-positive population with normal 2-hour glucose levels: implications for current staging … | Diabetes care | Brandon M Nathan Maria J Redondo Heba Ismail Laura Jacobsen Emily K Sims | 2022/2/1 |
The transition from a compensatory increase to a decrease in C-peptide during the progression to type 1 diabetes and its relation to risk | Diabetes Care | Heba M. Ismail ORCID logo David Cuthbertson Stephen E. Gitelman Jay S. Skyler Andrea K. Steck | 2022 |
